HSPA5 and neoplasm: V. A. Brentville et al. demonstrated the existence of a repertoire of responses to citrullinated GRP78 peptides in healthy individuals, with 76% of healthy individuals responding to this peptide, and with citrullinated GRP78 peptides as a potential tumor antigen, targeted vaccines may provide a promising approach for future cancer treatment [79].